Extracellular membrane vesicle or enveloped virus binding system, preparation method and application thereof

Through the modification of Tim4 protein and biotin labeling technology, combined with solid-phase vector, the efficient purification and removal of extracellular membrane vesicles and envelope viruses are solved, and efficient and low-cost extracellular membrane vesicles and envelope viruses are achieved. The identification and separation of the product is suitable for diagnostic and pharmaceutical applications.

CN118091112BActive Publication Date: 2024-11-22BEYOTIME BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410245395.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-04
Publication Date
2024-11-22
Estimated Expiration
2044-03-04

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently obtain and purify extracellular membrane vesicles and envelope viruses, especially in diagnostic and pharmaceutical applications, and how to effectively remove extracellular membrane vesicles and envelopes from samples. Virus contamination problem.

Method used

The modification of Tim4 protein is achieved by combining the protein complex on the solid phase carrier to identify, isolate and remove extracellular membrane vesicles or envelope viruses through expression, site-directed biotin labeling and purification preparation methods. Specific steps include purification and detection using a protein complex on the solid phase carrier using the specific binding of the biotin-labeled engineered Tim4 protein to the solid phase carrier.

Benefits of technology

It realizes efficient identification, isolation and purification of outer membrane vesicles or envelope viruses from samples, improves detection sensitivity and purification efficiency, reduces production costs, and is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004726104990000131
    Figure BDA0004726104990000131
  • Figure HDA0004726105080000011
    Figure HDA0004726105080000011
  • Figure HDA0004726105080000012
    Figure HDA0004726105080000012
Patent Text Reader

Abstract

The present invention provides a binding system for extracellular membrane vesicles or enveloped viruses, a preparation method and an application thereof. A binding system suitable for identifying and separating extracellular membrane vesicles or enveloped viruses is disclosed based on the optimization and modification of Tim (T‑cell immunoglobulin and mucin domain) protein. Compared with the use of the entire extracellular segment protein of natural Tim4, the tandem expression of the IgV‑like domains of the Tim4 protein of mice and humans not only increases the expression amount of the recombinant protein and reduces the production cost, but also increases the density of the Tim4 protein in the local area, and the efficiency of the modified Tim4 protein in binding to extracellular vesicles or enveloped viruses is significantly increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to a binding system of extracellular membrane vesicles or enveloped viruses, a preparation method and application thereof. Background Art

[0002] Extracellular membrane vesicles contain proteins, small RNA (microRNA) and other nucleic acids inside their particles, which are responsible for the transfer of substances between cells. Extracellular membrane vesicles are also secreted into body fluids such as blood, and proteins and small RNA (microRNA) in extracellular membrane vesicles have attracted attention as diagnostic markers for diseases. In addition, their application as a delivery tool for nucleic acid drugs has also attracted attention.

[0003] Among viruses, there is a class of enveloped viruses whose surface is covered with a membrane-like envelope. Most enveloped viruses are viruses that cause diseases, such as influenza viruses and human immunodeficiency viruses, and are a hot topic in this field. For example, those skilled in the art inactivate enveloped viruses, use them as vaccines, carriers, etc., and apply them to the prevention and treatment of diseases.

[0004] When applying extracellular membrane vesicles to diagnosis or medicines, using enveloped viruses as vaccines or vectors, or conducting basic research such as functional analysis of extracellular membrane vesicles or enveloped viruses, a process for obtaining extracellular membrane vesicles or enveloped viruses at high purity is essential.

[0005] Therefore, the art needs to develop a method that can easily obtain high-purity extracellular membrane vesicles and enveloped viruses. In addition, in order to prevent the contamination of extracellular membrane vesicles and enveloped viruses from organisms, it is also worth looking forward to developing a method for effectively removing extracellular membrane vesicles and enveloped viruses from various samples used. Furthermore, a method for highly sensitively detecting the obtained extracellular membrane vesicles, enveloped viruses, and extracellular membrane vesicles and enveloped viruses in the subject is also needed in the art. Summary of the invention

[0006] The purpose of the present invention is to provide a binding system for extracellular membrane vesicles or enveloped viruses, a preparation method and application thereof. In a specific scheme, the present invention provides the modification of Tim4 protein, its expression, site-specific biotin labeling and purification preparation method, and a method for purifying, removing and detecting extracellular vesicles or viruses using the modified Tim4 protein labeled with biotin, etc.

[0007] In a first aspect of the present invention, a method for identifying (including detecting) and separating (including purifying) extracellular membrane vesicles or enveloped viruses from a sample is provided, comprising:

[0008] (1) Providing a binding system, comprising a solid phase carrier, and a protein complex located on the solid phase carrier; the protein complex comprises: an IgV-like domain of a human Tim4 protein, a flexible linker, and an IgV-like domain of a mouse Tim4 protein, which are operably connected;

[0009] (2) The sample is added to the binding system of (1) to identify and separate the extracellular membrane vesicles or enveloped viruses.

[0010] In one or more embodiments, the solid phase carrier includes (but is not limited to): microparticles (such as magnetic beads), membranes (such as nylon membranes), ELISA plates, dishes, glass slides or silicon wafers, plastic sheets, test papers, etc.

[0011] In one or more embodiments, the identification and separation include: detecting, separating, purifying, and removing extracellular membrane vesicles or enveloped viruses in a sample.

[0012] In one or more embodiments, the carboxyl end of the protein complex includes a tag, and the tag carries conjugate 1; the solid phase carrier includes conjugate 2, and the conjugate 2 specifically binds to the conjugate 1, and the protein complex is fixed to the solid phase carrier through the binding.

[0013] In one or more embodiments, the conjugate 1 is biotin and the conjugate 2 is avidin; more preferably, the carboxyl terminus includes a tag Avi, and the biotin is connected to the tag Avi (more preferably, BirA is used to specifically connect biotin to the lysine residue of the Avi tag).

[0014] In one or more embodiments, the tag further comprises a purification tag (including but not limited to: His, Flag, Myc, HA, V5, VSV-G, etc.).

[0015] In one or more embodiments, the amino acid sequence of the IgV-like domain of the human Tim4 protein is as shown in SEQ ID NO:11.

[0016] In one or more embodiments, the amino acid sequence of the IgV-like domain of the mouse Tim4 protein is as shown in SEQ ID NO:12.

[0017] In one or more embodiments, the flexible linker is (GGGGGS)n, wherein n is a positive integer of 1-15, preferably a positive integer of 4-12, and more preferably a positive integer of 5-10 (such as 6, 7, 8, 9, and the best is 6).

[0018] In one or more embodiments, the N-terminus of the protein complex further includes a signal peptide, which enables the protein complex to be secreted and expressed.

[0019] In one or more embodiments, the signal peptide is a signal peptide from human Tim4 protein or mouse Tim4 protein, and its amino acid sequence is shown in SEQ ID NO: 17 or SEQ ID NO: 18; preferably, the signal peptide is a signal peptide from human Tim4 protein.

[0020] In one or more embodiments, the amino acid sequence of the IgV-like domains of human and mouse Tim4 proteins expressed in tandem is as shown in SEQ ID NO:19.

[0021] In one or more embodiments, the codon-optimized base sequence for expressing the IgV-like domains of human Tim4 and mouse Tim4 in tandem with the flexible linker sequence is as shown in SEQ ID NO:29.

[0022] In one or more embodiments, in step (2), the binding system is in Ca 2+ Binds to extracellular vesicles or enveloped viruses in the presence of

[0023] In one or more embodiments, after step (2), a step of detecting extracellular membrane vesicles or enveloped viruses is also included.

[0024] In one or more embodiments, the detection is performed using ELISA or flow cytometry.

[0025] In one or more embodiments, extracellular vesicles or enveloped viruses are detected by sandwich ELISA using antibodies against extracellular vesicles or enveloped virus surface antigens.

[0026] In another aspect of the present invention, a protein complex, a polynucleotide encoding the same, or an expression construct (expression vector) containing the polynucleotide is provided; wherein the protein complex includes: an IgV-like domain of human Tim4 protein, a flexible linker, and an IgV-like domain of mouse Tim4 protein that are operably connected.

[0027] In one or more embodiments, the amino terminus of the protein complex further includes a signal peptide.

[0028] In one or more embodiments, the carboxyl terminus of the protein complex further comprises a tag; preferably, the tag comprises an Avi tag; more preferably, the tag further comprises a purification tag.

[0029] In another aspect of the present invention, a method for preparing the protein complex is provided, comprising: providing a polynucleotide encoding the protein complex, introducing it into eukaryotic cells using an expression construct (expression vector), and performing recombinant expression in suspended cells; preferably, the eukaryotic cells include: 293 cells, CHO cells.

[0030] In one or more embodiments, the cells include, but are not limited to, Expi293F, Freestyle 293-F, HEK293F, HEK293Expi, CHO-K1, ExpiCHO, and Freestyle CHO.

[0031] In another aspect of the present invention, a binding system for identifying and separating extracellular membrane vesicles or enveloped viruses from a sample is provided, comprising: a solid phase carrier, and the protein complex located on the solid phase carrier.

[0032] In another aspect of the present invention, a method for preparing the binding system is provided, comprising: preparing a protein complex using the method described, wherein the carboxyl end of the protein complex comprises a label, and the label can be connected to conjugate 1; fixing the protein complex on a solid phase carrier, wherein the solid phase carrier comprises conjugate 2, and the conjugate 2 specifically binds to conjugate 1.

[0033] In one or more embodiments, the conjugate 1 is biotin and the conjugate 2 is avidin; more preferably, the carboxyl end includes a tag Avi, and the biotin is connected to the tag Avi.

[0034] In one or more embodiments, the tag is also provided with a purification tag.

[0035] In another aspect of the present invention, a kit for identifying and isolating extracellular membrane vesicles or enveloped viruses from a sample is provided, comprising: the protein complex, a polynucleotide encoding the complex, or an expression construct (expression vector) containing the polynucleotide.

[0036] In another aspect of the present invention, a kit for identifying and separating extracellular membrane vesicles or enveloped viruses from a sample is provided, which comprises the aforementioned binding system for identifying and separating extracellular membrane vesicles or enveloped viruses from a sample.

[0037] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 This is a schematic diagram of the three-dimensional structure of the IgV-like domain of human and mouse Tim1, Tim3 and Tim4 proteins.

[0039] Figure 2 Schematic diagram of a hydrophobic PS binding pocket formed by the CC' loop and FG loop of the IgV-like domain of human and mouse Tim1, Tim3 and Tim4 proteins.

[0040] Figure 3 This is a schematic diagram of the molecular mechanism of recognition and binding between the IgV-like domains of human and mouse Tim1, Tim3 and Tim4 proteins and PS.

[0041] Figure 4 The efficiency of recognizing and binding to PS on the surface of extracellular vesicles or viruses by ELISA determination of the IgV-like domains of human and mouse Tim4 proteins expressed in series and 2 human Tim4 protein IgV-like domains, 2 mouse Tim4 protein IgV-like domains, human Tim4 protein IgV-like domain and mouse Tim4 protein IgV-like domain.

[0042] Figure 5 This is a graph showing the efficiency of recognizing and binding to PS on the surface of extracellular vesicles or viruses by expressing the IgV-like domain of human and mouse Tim4 proteins in tandem with different flexible linker sequences using ELISA.

[0043] Figure 6 The efficiency of the IgV-like domain of human and mouse Tim4 protein expressed in tandem with different numbers of repetitions of the GGGGGS flexible linker sequence in recognizing and binding to PS on the surface of extracellular vesicles or viruses was measured by ELISA.

[0044] Figure 7 This is a schematic diagram of the biotin labeling of Avi-tagged proteins by BirA.

[0045] Figure 8 This is a schematic diagram of the modification of the Tim4 protein C-terminus by fusing the His tag and Avi tag.

[0046] Fig. 9 This is a Western Blot diagram exploring the concentration of BirA biotin-labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4IgV-His-Avi).

[0047] Fig.10 This is a Western Blot diagram exploring the optimal reaction time of BirA biotin-labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4IgV-His-Avi).

[0048] Fig.11This is a Western Blot image verifying the expression of the modified Tim4 protein in the supernatant of the culture medium of (hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi) HEK293F suspension cells.

[0049] Fig.12 This is a schematic diagram of the purification process of biotin-labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi).

[0050] Fig.13 This is the SDS-PAGE gel electrophoresis of the purified biotin-labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4IgV-His-Avi).

[0051] Fig.14 This is a Western Blot image of streptavidin magnetic beads bound to different amounts of biotin-labeled modified Tim4 protein (hTim4IgV-(GGGGGS)6-mTim4 IgV-His-Avi).

[0052] Fig.15 This is a Western Blot image of streptavidin gel combined with different amounts of biotin-labeled modified Tim4 protein (hTim4IgV-(GGGGGS)6-mTim4 IgV-His-Avi).

[0053] Fig.16 This is a Western Blot effect diagram of purifying extracellular vesicles using magnetic beads modified with Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi).

[0054] Fig.17 A is a schematic diagram of the topological structure of Tim4-Fc protein randomly labeled with biotin.

[0055] Fig.17 B is a schematic diagram of the topological structure of the modified Tim4 protein labeled with biotin.

[0056] Fig.18 A is a schematic diagram of biotin-randomly labeled Tim4-Fc protein bound to streptavidin magnetic beads or gel surface.

[0057] Fig.18 B is a schematic diagram of biotin site-specifically labeled modified Tim4 protein bound to streptavidin magnetic beads or gel surface.

[0058] Fig.19This is a Western Blot effect diagram of the extracellular vesicles purified by biotin-site-labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4IgV-His-Avi) and biotin-randomly labeled Tim4-Fc protein combined with streptavidin magnetic beads.

[0059] Fig. 20 This is a graph showing the efficiency of purifying extracellular vesicles by combining biotin-specifically labeled modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4IgV-His-Avi) with biotin-randomly labeled Tim4-Fc protein and streptavidin magnetic beads. DETAILED DESCRIPTION

[0060] After in-depth research, the inventors have revealed a binding system suitable for identifying and separating extracellular membrane vesicles or enveloped viruses based on the optimization and modification of Tim (T-cell immunoglobulin and mucin domain) protein. The binding system can efficiently identify and separate extracellular membrane vesicles or enveloped viruses from a sample.

[0061] As used in the present invention, the "extracellular vesicles" and "extracellular membrane vesicles" can be used interchangeably.

[0062] As used in the present invention, unless otherwise specified, the "protein complex" and the "modified Tim4 protein" are used interchangeably.

[0063] As used in the present invention, the "binding system" includes a solid phase carrier and a protein complex located on the solid phase carrier.

[0064] As used in the present invention, the term "operably linked" or "operably connected" refers to the functional spatial arrangement of two or more nucleic acid regions or protein domains. For example, a promoter region is placed at a specific position relative to a gene nucleic acid sequence, so that transcription of the nucleic acid sequence is guided by the promoter region, and thus the promoter region is "operably linked" to the nucleic acid sequence.

[0065] In the present invention, the immunoglobulin variable-like (IgV-like) domains of human and mouse T cell immunoglobulin mucin 4 are expressed in tandem to increase the density of Tim4 in the local area, thereby increasing the binding efficiency of Tim4 protein with phosphotidylserine (PS) on the surface of extracellular vesicles or viruses.

[0066] In the present invention, the extracellular membrane vesicles are small membrane vesicles secreted by cells or cultured cells, composed of a lipid bilayer membrane and having phosphatidylserine on the membrane surface. The diameter of the vesicle is usually 10nm to 1000nm, and also includes some special vesicles below 10nm or above 1000nm.

[0067] In the present invention, the extracellular membrane vesicles can be a variety of vesicles, such as but not limited to: microvesicles, exosomes, membrane particles, ectosomes, exosome-like vesicles, apoptotic vesicles, adiposomes, etc. Among them, microvesicles are small membrane vesicles derived from cell membranes, composed of lipid bilayer membranes and having phosphatidylserine on the membrane surface. Exosomes are small membrane vesicles derived from late endosomes, composed of lipid bilayer membranes and having phosphatidylserine on the membrane surface. Membrane particles are small membrane vesicles derived from cell membranes, composed of lipid bilayer membranes and having phosphatidylserine on the membrane surface. Ectosomes are small membrane vesicles derived from cell membranes, composed of lipid bilayer membranes and having phosphatidylserine on the membrane surface. Exosome-like vesicles are small membrane vesicles derived from early endosomes, composed of a lipid bilayer membrane and having phosphatidylserine on the membrane surface. Apoptotic vesicles are small membrane vesicles derived from apoptotic cells, composed of a lipid bilayer membrane and having phosphatidylserine on the membrane surface. Fat bodies are small membrane vesicles derived from adipocytes, composed of a lipid bilayer membrane and having phosphatidylserine on the membrane surface.

[0068] In the present invention, the virus is a virus having an envelope (envelop) composed of a lipid bilayer membrane derived from a cell membrane, a nuclear membrane, a Golgi apparatus, an endoplasmic reticulum, etc. of a host cell in the capsid (shell) of the virus, and having phosphatidylserine on the surface of the envelope, which is also referred to as "enveloped virus" in the present invention. The enveloped virus may include (but is not limited to): Poxviridae, Baculoviridae, Rhabdoviridae, Bunyaviridae, Togaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae, Retrovirus, Arenaviridae, Coronaviridae, etc.

[0069] It should be understood that the enveloped viruses described in the present invention have the same components as extracellular vesicles. After listing the technical effects related to extracellular vesicles in the embodiments, it can be expected that the technical scheme of the present invention is also applicable to the identification and separation of enveloped viruses.

[0070] In the present invention, the Tim protein includes: at least one Tim protein selected from the group consisting of T cell immunoglobulin and mucin domain molecule 1 (Tim1) protein, T cell immunoglobulin and mucin domain molecule 3 (Tim3) protein, and T cell immunoglobulin and mucin domain molecule 4 (Tim4) protein.

[0071] In a preferred embodiment of the present invention, the modified Tim4 protein uses the IgV-like domain of Tim4 (SEQ ID NO: 11) and the IgV-like domain of mouse Tim4 protein (SEQ ID NO: 12). The modified Tim1 protein used in the embodiment of the present invention uses the IgV-like domain of human Tim1 protein (SEQ ID NO: 7) and the IgV-like domain of mouse Tim1 protein (SEQ ID NO: 8), and the modified Tim3 protein uses the IgV-like domain of human Tim3 protein (SEQ ID NO: 9) and the IgV-like domain of mouse Tim3 protein (SEQ ID NO: 10).

[0072] In a preferred embodiment of the present invention, a modified Tim4 protein is provided, which expresses the IgV-like domains of human and mouse Tim4 proteins in tandem with a flexible linker sequence (preferably (GGGGGS)6), and secretes the modified Tim4 protein into the culture medium supernatant through the secretory signal peptide (SP) of the human Tim4 protein.

[0073] The number of repetitions of the sequence of the flexible linker includes (but is not limited to): 1-15 times. The sequence of the flexible linker may include (but is not limited to): GGGGGS, GSGGGS, GSGSGS, GGGGSS, GSSGSS, GSSSSSS and SSSSSSS. In a preferred embodiment, the sequence of the flexible linker is GGGGGS, and the number of repetitions of GGGGGS is 6.

[0074] In a preferred embodiment, the modified Tim4 protein uses the IgV-like domains of human and mouse Tim4 proteins (SEQ ID NO: 19) expressed in series by a flexible linker (GGGGGS) 6. The better modified Tim4 protein uses the IgV-like domains of two human Tim4 proteins (SEQ ID NO: 20) or the IgV-like domains of two mouse Tim4 proteins (SEQ ID NO: 21) expressed in series by a flexible linker (GGGGGS) 6.

[0075] In a more preferred embodiment of the present invention, the secretion signal peptide of human Tim4 protein (SEQ ID NO: 17) is used to secrete the modified Tim4 protein into the culture supernatant. Preferred secretion signal peptides include (but are not limited to): secretion signal peptide of human Tim1 protein (SEQ ID NO: 13), secretion signal peptide of human Tim3 protein (SEQ ID NO: 15), secretion signal peptide of mouse Tim1 protein (SEQ ID NO: 14), secretion signal peptide of mouse Tim3 protein (SEQ ID NO: 16), secretion signal peptide of mouse Tim4 protein (SEQ ID NO: 18).

[0076] The present invention also includes fragments, derivatives and analogs of the above-mentioned elements (human or mouse Tim4 or its IgV-like domain, flexible linker, signal peptide and other structures used to form protein complexes). As used herein, the terms "fragment", "derivative" and "analog" refer to protein fragments that substantially maintain the same biological function or activity of the polypeptide, which may be (i) a protein with one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) replaced, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a protein with a substitution group in one or more amino acid residues, or (iii) a protein formed by the fusion of an additional amino acid sequence to this protein sequence, etc. According to the definition herein, these fragments, derivatives and analogs belong to the scope known to those skilled in the art. The biologically active fragments of the elements can be applied to the present invention.

[0077] The elements also include sequence variants with the same function as the protein. These variants include (but are not limited to): deletion, insertion and / or substitution of several (usually 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, and even more preferably 1-8, 1-5) amino acids, and addition or deletion of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed.

[0078] The vectors containing the coding sequences of the elements, and the host cells produced by genetic engineering using the vectors or polypeptide coding sequences are also included in the present invention. Methods well known to those skilled in the art can be used to construct suitable expression vectors.

[0079] In a preferred embodiment of the present invention, a method for modifying Tim4 protein by biotin labeling is provided, including: modifying the fusion expression of Tim4 and Avi tag, and an experimental method in which BirA specifically connects biotin to the lysine residue of the Avi tag.

[0080] In a preferred embodiment, biotin is specifically linked to the lysine residue of the Avi tag fused to the C-terminus of the Tim4 protein by the BirA enzyme. Compared with randomly linking biotin to amino, carbonyl, sulfhydryl and other molecules on the surface of the Tim4 protein by chemical methods, the reaction conditions of the present invention are mild, the biotin labeling efficiency is high, and the experimental repeatability is good.

[0081] In a preferred embodiment, the purification tag and Avi tag are fused to the C-terminus of the modified Tim4 (hTim4IgV-(GGGGGS)6-mTim4 IgV-His-Avi) (SEQ ID NO: 22) when expressing the construct. The purification tag may include (but is not limited to): His tag, Flag tag, Myc tag, HA tag, V5 tag and VSV-G tag, etc. For example, a His tag with 6-10 histidine repeats is used.

[0082] In a preferred embodiment, when the Avi tag of the modified Tim4 protein is biotin-labeled with BirA, the concentration of the modified Tim4 protein is 10-100 μM, preferably 40±20 μM or 40±10 μM or 40±5 μM; the reaction temperature is 4-37°C, preferably 30±6°C or 30±5°C or 30±3°C or 30±2°C or 30±1°C; the reaction time is 1-12 hours, preferably 6±5 hours or 6±3 hours or 6±2 hours or 6±1 hour.

[0083] In a preferred embodiment of the present invention, a method for expressing and purifying modified Tim4 protein is provided. Eukaryotic cells are used to purify modified Tim4 protein. Preferred eukaryotic cells include yeast cells, mold cells, insect cells, plant cells, and fungal cells. In a preferred embodiment, HEK293F suspension cells are used for expression; the preferred eukaryotic cells include (but are not limited to): Expi293F TM 、Freestyle TM 293-F, HEK293F, HEK293Expi, CHO-K1, ExpiCHO TM and Freestyle TM CHO and other eukaryotic cells.

[0084] In a preferred embodiment, the culture supernatant expressing the modified Tim4 protein is purified by using a reduction-resistant chelating nickel affinity chromatography resin, and after elution, the solution is replaced into 1X PBS through a desalting column. After the modified Tim4 is concentrated through a 10kDa ultrafiltration tube, the modified Tim4 is biotin-labeled with BirA, and purified again using a reduction-resistant chelating nickel affinity chromatography resin. After elution, the purification of the biotin-labeled modified Tim4 protein is completed.

[0085] In a preferred embodiment of the present invention, a method is provided for purifying or removing extracellular vesicles or enveloped viruses with higher efficiency and loading capacity by using biotin-labeled modified Tim4 protein connected to streptavidin magnetic beads or gel beads.

[0086] In a preferred embodiment, 1 mg of streptavidin magnetic beads can bind 10-100 μg of biotin-labeled modified Tim4 protein, which can bind 1×109 -1×10 10 extracellular vesicles or enveloped viruses.

[0087] In a preferred embodiment, 0.1 ml of streptavidin gel can bind 50-500 μg of biotin-labeled modified Tim4 protein, which can bind 5×10 9 -5×10 10 extracellular vesicles or enveloped viruses.

[0088] In a preferred embodiment, the binding solution of streptavidin magnetic beads or gel and biotin-labeled modified Tim4 protein includes: TBS, 0.0005-0.05% Tween-20, 0.01%-0.1% BSA; the washing solution includes: TBS, 0.0005-0.05% Tween-20.

[0089] In a preferred embodiment, the biotin-labeled modified Tim4 protein connected to streptavidin magnetic beads or gel-bound extracellular vesicles or enveloped viruses solution includes: TBS, 0.0005-0.05% Tween-20, 0.01%-0.1% BSA, 5-25mM CaCl2; the elution solution includes: PBS, 5-25mM EDTA pH8.0.

[0090] In a preferred embodiment of the present invention, a biotin-labeled modified Tim4 protein-encapsulated ELISA plate is provided. 2+ A method for binding to extracellular vesicles or enveloped viruses under the presence of antibodies, detecting extracellular vesicles or enveloped viruses with high sensitivity through sandwich ELISA using antibodies against surface antigens of extracellular vesicles or enveloped viruses.

[0091] In a preferred embodiment, the concentration of the modified Tim4 protein coated ELISA plate is 0.5-2 μg / ml, and the solution for binding extracellular vesicles or enveloped viruses includes: TBS, 1-5 mM CaCl2; and the washing solution includes: TBS, 0.0005-0.05% Tween-20.

[0092] In a preferred manner, the antibody against the surface antigen of the extracellular vesicle or enveloped virus is coupled with a horseradish peroxide marker, and the antibody is used at a concentration of 0.5-2 μg / ml. Preferably, an enzyme-labeled antibody labeled with an enzyme such as alkaline phosphatase can be used. In addition, a fluorescent-labeled antibody labeled with a fluorescent substance such as Cy3, Cy5, FITC, rhodamine, PE, etc. can also be used. Preferably, an unlabeled antibody against the surface antigen of the extracellular vesicle or enveloped virus can be used in combination with a secondary antibody labeled with horseradish peroxide, alkaline phosphatase or fluorescence.

[0093] The modified biotin-labeled Tim4 protein of the present invention is combined with streptavidin magnetic beads or gel, and can be used to purify, remove and detect extracellular vesicles or viruses in samples. Compared with the randomly biotin-labeled Tim4 protein, the biotin labeling position of the modified Tim4 protein of the present invention is determined, the modified Tim4 protein can be bound to the surface of the streptavidin magnetic beads or gel at a fixed angle, the PS binding site of the Tim4 protein away from the C-terminus is more fully exposed, and the PS binding activity is little affected by the fixation on the surface of the magnetic beads or gel, so the magnetic beads or gel prepared by the modified Tim4 protein have a higher efficiency in capturing extracellular vesicles or viruses in the sample; and by expressing the mouse and human Tim4 IgV-like domains in series, the number of Tim4 proteins on the streptavidin magnetic beads or gel is indirectly increased, thereby improving the load and ability of the magnetic beads or gel prepared by the modified Tim4 protein to capture extracellular vesicles or viruses in the sample.

[0094] The present invention also provides methods for modifying the expression, biotin labeling and purification of Tim4 protein, providing a method with high yield, low production cost and suitability for large-scale production for purifying, removing and highly sensitively detecting intact extracellular vesicles or viruses in samples.

[0095] The main beneficial effects of the present invention include:

[0096] Compared with using the entire extracellular segment of natural Tim4 protein, tandem expression of mouse and human Tim4 protein IgV-like domains not only increases the expression level of recombinant protein and reduces production costs, but also increases the density of Tim4 protein in local areas, and significantly increases the efficiency of modified Tim4 protein binding to extracellular vesicles or virus surface PS.

[0097] The random attachment of biotin to the amino, carbonyl, sulfhydryl and other molecules on the surface of Tim4 protein by chemical methods has the disadvantages of expensive labeling kits, complicated operation, differences in protein recovery rate, biotin labeling effect between batches, and random and indiscriminate biotin labeling that affects the biological activity of Tim4 protein binding to PS. The specific attachment of biotin to the lysine residue of the Avi tag fused to the C-terminus of Tim4 protein by BirA enzyme has low labeling cost, good experimental repeatability, high protein recovery rate, mild reaction conditions, high biotin labeling efficiency, and does not affect the biological activity of Tim4 protein binding to PS at all.

[0098] When the randomly biotin-labeled Tim4 protein binds to the surface of streptavidin magnetic beads or gel, it binds at different angles like rolling dice. The hydrophobic PS binding pockets of some Tim4 proteins are physically blocked by the surface of magnetic beads or gel, resulting in a decrease in the PS binding titer of Tim4 proteins bound to streptavidin magnetic beads or gel. The modified Tim4 protein is bound to the surface of streptavidin magnetic beads or gel at a fixed angle through a biotin label specifically located at the C-terminus, and the PS binding site far from the C-terminus is fully exposed. Therefore, the magnetic beads or gels prepared with modified Tim4 proteins have a higher efficiency in capturing extracellular vesicles or viruses in samples.

[0099] Compared to simply binding the entire extracellular segment of native mouse or human Tim4 protein to streptavidin magnetic beads or gel, the number of PS binding sites on streptavidin magnetic beads or gel bound by tandemly expressed mouse and human Tim4 proteins is doubled, thereby improving the efficiency and loading capacity of magnetic beads or gels in capturing extracellular vesicles or viruses in samples.

[0100] In summary, the Tim4 protein modified according to the present invention is labeled with biotin at a specific site and then combined with streptavidin magnetic beads or gel, which can be more effective, lower cost, and more suitable for large-scale purification, removal and high-sensitivity detection of intact extracellular vesicles or enveloped viruses in samples.

[0101] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0102] Example 1. Expressing the IgV-like domains of human and mouse Tim4 proteins in series through a flexible linker to enhance the efficiency of Tim4 protein binding to extracellular vesicles or PS on the surface of viruses

[0103] 1. Structural analysis of Tim protein

[0104] The N-terminus of the Tim family consists of an IgV-like domain and a highly glycosylated mucin-like domain outside the cell membrane, and is anchored on the cell surface through a single transmembrane. The C-terminus of the Tim1 and Tim3 proteins in the cell membrane contains tyrosine phosphorylation sequences that participate in signal transduction after ligand binding, and the Tim4 protein does not contain tyrosine phosphorylation sequences. The full-length amino acid sequence of human Tim1 (hTim1) protein is shown in SEQ ID NO: 1, the full-length amino acid sequence of mouse Tim1 (mTim1) protein is shown in SEQ ID NO: 2, the full-length amino acid sequence of human Tim3 (hTim3) protein is shown in SEQ ID NO: 3, the full-length amino acid sequence of mouse Tim3 (mTim3) protein is shown in SEQ ID NO: 4, the full-length amino acid sequence of human Tim4 (hTim4) protein is shown in SEQ ID NO: 5, and the full-length amino acid sequence of mouse Tim4 (mTim4) protein is shown in SEQ ID NO: 6.

[0105] The IgV-like domains of Tim1, Tim3 and Tim4 proteins are directly involved in the recognition and binding of PS. The amino acid sequence of the IgV-like domain of human Tim1 protein is shown in SEQ ID NO:7, the amino acid sequence of the IgV-like domain of mouse Tim1 protein is shown in SEQ ID NO:8, the amino acid sequence of the IgV-like domain of human Tim3 protein is shown in SEQ ID NO:9, the amino acid sequence of the IgV-like domain of mouse Tim3 protein is shown in SEQ ID NO:10, the amino acid sequence of the IgV-like domain of human Tim4 protein is shown in SEQ ID NO:11, and the amino acid sequence of the IgV-like domain of mouse Tim4 protein is shown in SEQ ID NO:12.

[0106] Analysis of protein crystal structures showed that the topological structures of the IgV-like domains of hTim1 (PDB code 5F70), mTim1 (PDB code 2OR8), hTim3 (PDB code 5F71), mTim3 (PDB code 3KAA), hTim4 (PDB code 5F7F) and mTim4 (PDB code 3BI9) were highly similar ( Figure 1 ): It is composed of two sets of antiparallel BEDβ sheets and GFCβ sheets. Six conserved cysteines form three pairs of conserved disulfide bonds. One pair of disulfide bonds connects the two sets of β sheets to stabilize the IgV-like overall domain. The other two pairs of disulfide bonds stabilize the CC'loop on one side of the GFCβ sheet, so that the CC'loop and FGloop form a hydrophobic PS binding pocket ( Figure 2), the two conserved amino acids in the FG loop (asparagine and aspartic acid) are used to bind Ca 2+ Stabilize the negatively charged phosphate groups in PS to achieve recognition and binding of Tim protein to PS ( Figure 3 ).

[0107] 2. Enhance the efficiency of Tim4 protein binding to PS on extracellular vesicles or virus surface by tandemly expressing the IgV-like domains of human and mouse Tim4 proteins

[0108] In order to improve the efficiency of Tim4 protein in recognizing and binding PS on the surface of extracellular vesicles or viruses, the inventors have repeatedly analyzed and studied, and based on the structure of natural Tim1, Tim3 and Tim4 proteins, connected IgV-like domains in series by flexible linkers to increase the density of PS binding regions in local areas. Analysis shows that the efficiency of the IgV-like domain of Tim4 protein in recognizing and binding PS is higher than that of the IgV-like domains of Tim1 and Tim3 proteins. The inventors selected the IgV-like domains of human and / or mouse Tim4 proteins in series, and tested a variety of expression schemes connected by flexible linkers (GGGGGS), including:

[0109] Tandemly express the IgV-like domains of human and mouse Tim4 proteins (SEQ ID NO: 19);

[0110] Tandem expression of two IgV-like domains of human Tim4 protein (SEQ ID NO: 20);

[0111] Two IgV-like domains of mouse Tim4 protein (SEQ ID NO: 21) were expressed in tandem.

[0112] ELISA experiments were used to analyze the efficiency of tandem proteins in recognizing and binding to PS on the surface of extracellular vesicles or viruses. ELISA assay method: In a 96-well ELISA plate, 100 μl of human Tim4 protein IgV-like domain (hTim4 IgV), mouse Tim4 protein IgV-like domain (mTim4 IgV), tandem expression of human and mouse Tim4 protein IgV-like domain (hTim4 IgV-(GGGGGS)6-mTim4 IgV), tandem expression of two human Tim4 protein IgV-like domains (hTim4 IgV-(GGGGGS)6-hTim4 IgV) and tandem expression of two mouse Tim4 protein IgV-like domains (mTim4 IgV-(GGGGGS)6-mTim4 IgV) were added to each well, and each protein was repeated in 6 wells and incubated overnight at 4°C. After removing each protein solution, add 200μl TBS to each well and wash 3 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. After removing the washing solution, add 200μl blocking solution (TBS containing 5% BSA) to each well and incubate at room temperature for 2 hours. After removing the blocking solution, add 200μl TBS to each well and wash 3 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. The supernatant of HEK293F suspended cells cultured in serum-free medium was diluted after ultracentrifugation to make the total protein concentration 2mg / ml, 1mg / ml, 0.5mg / ml, 0.25mg / ml and 0.125mg / ml, respectively, and contain 2mMCaCl2, and 100μl of each was added to each well of 5 wells, and TBS containing 2mM CaCl2 was added to the blank control well and incubated at room temperature for 3 hours. After removing the sample solution, add 200μl of TBS containing 2mM CaCl2 to each well and wash 3 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. After removing the washing solution, add 200μl of Biotin-labeled recombinant CD81 antibody diluted with 2mM CaCl2 in TBS to each well and incubate for 2 hours at room temperature. After removing the primary antibody solution, add 200μl of TBS containing 2mM CaCl2 to each well and wash 3 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. After removing the washing solution, add 200μl of HRP-labeled Streptavidin diluted with 2mM CaCl2 in TBS to each well and incubate for 1 hour at room temperature. After removing the secondary antibody solution, add 200μl of TBS containing 2mM CaCl2 to each well and wash 5 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time.After removing the washing solution, 100 μl of enhanced TMB colorimetric solution was added to each well. After incubation at room temperature in the dark for 30 minutes, 100 μl of TMB colorimetric stop solution was added to each well, and the absorbance at 450 nm was detected using an enzyme-labeled instrument.

[0113] ELISA assays revealed that the tandem expression of the IgV-like domains of human and mouse Tim4 proteins had significantly higher efficiency in recognizing and binding to PS on the surface of extracellular vesicles or viruses than the tandem expression of two human Tim4 protein IgV-like domains, two mouse Tim4 protein IgV-like domains, a human Tim4 protein IgV-like domain, and a mouse Tim4 protein IgV-like domain ( Figure 4 ).

[0114] 3. Screening of amino acid composition and length of flexible linkers

[0115] Linkers are divided into flexible linkers, rigid linkers and cleavable linkers. The inventors' experimental analysis shows that the recognition and binding of the IgV-like domain to the PS on the surface of extracellular vesicles or viruses requires a certain spatial distance. Therefore, a suitable flexible linker is selected to connect the two IgV-like domains, and the effects of the amino acid composition and length of the flexible linker on the expression level, stability and protein activity of the protein are analyzed. Non-polar hydrophobic amino acids: glycine (G) and serine (S) are the most widely used amino acids for flexible linkers. The inventors have tested a variety of flexible linker amino acid compositions: GGGGGS, GSGGGS, GSGSGS, GGGGSS, GSSGSS, GSSSSSS and SSSSSSS. As the glycine content decreases, the hardness of the linker increases. In order to ensure the independent spatial stretchability of the two IgV-like domains of the tandem Tim4 protein, GGGGGS is selected as the flexible linker ( Figure 5 ).

[0116] Flexible linkers of different lengths affect the ability of the two IgV-like domains to recognize and bind to PS, the yield and stability of the fusion protein to a certain extent. ELISA assay was used to test GGGGGS flexible linkers with 2-14 repeats. ELISA assay method: In a 96-well ELISA plate, 100 μl of the IgV-like domains of human and mouse Tim4 proteins expressed in series by different flexible linkers were added to each well: hTim4 IgV-(GGGGGS)6-mTim4 IgV, hTim4IgV-(GSGGGS)6-mTim4 IgV, hTim4 IgV-(GSGSGS)6-mTim4 IgV, hTim4IgV-(GGGGSS)6-mTim4IgV, hTim4 IgV-(GSSGSS)6-mTim4 IgV, hTim4IgV-(GSSSSSS)6-mTim4 IgV, hTim4IgV-(SSSSSSS)6-mTim4 IgV, hTim4IgV-(GGGGGS)6-mTim4 IgV, hTim4 IgV-(GGGGGS)4-mTim4IgV, hTim4IgV-(GGGGGS)8-mTim4 IgV, hTim4 IgV-(GGGGGS) 10 -mTim4 IgV, hTim4IgV-(GGGGGS)12-mTim4 IgV and hTim4 IgV-(GGGGGS) 14-mTim4 IgV, each protein was repeated in 6 wells, and incubated at 4°C overnight. After removing each protein solution, 200μl TBS was added to each well and washed 3 times, each time for 2-3 minutes, and the last time was placed on thick absorbent paper and patted dry. After removing the washing solution, 200μl blocking solution (TBS containing 5% BSA) was added to each well and incubated at room temperature for 2 hours. After removing the blocking solution, 200μl TBS was added to each well and washed 3 times, each time for 2-3 minutes, and the last time was placed on thick absorbent paper and patted dry. The supernatant of HEK293F suspended cells cultured in serum-free medium was diluted after ultracentrifugation to make the total protein concentration 2mg / ml, 1mg / ml, 0.5mg / ml, 0.25mg / ml and 0.125mg / ml, respectively, and 2mM CaCl2 was added to each well of 5 wells, and TBS containing 2mM CaCl2 was added to the blank control well, and incubated at room temperature for 3 hours. After removing the sample solution, 200μl of TBS containing 2mMCaCl2 was added to each well and washed 3 times, each incubation was 2-3 minutes, and the last time was placed on thick absorbent paper and patted dry. After removing the washing solution, 200μl of Biotin-labeled recombinant CD81 antibody diluted with 2mM CaCl2 TBS was added to each well and incubated at room temperature for 2 hours. After removing the primary antibody solution, add 200μl TBS containing 2mM CaCl2 to each well and wash 3 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. After removing the washing solution, add 200μl HRP-labeled Streptavidin diluted with 2mM CaCl2 in TBS to each well and incubate at room temperature for 1 hour. After removing the secondary antibody solution, add 200μl TBS containing 2mM CaCl2 to each well and wash 5 times, incubate for 2-3 minutes each time, and pat dry on thick absorbent paper for the last time. After removing the washing solution, add 100μl enhanced TMB colorimetric solution to each well, incubate at room temperature in the dark for 30 minutes, add 100μl TMB colorimetric stop solution to each well, and detect the absorbance at 450nm with an enzyme reader.

[0117] The results showed that the recombinant protein with the flexible linker (GGGGGS)×6 connecting the human and mouse Tim4 protein IgV-like domain had the highest expression level and the strongest ability to bind to and recognize PS ( Figure 6 ).

[0118] Example 2: Biotin labeling of specific sites by fusing and expressing Avi tags at the C-terminus of modified Tim4 protein

[0119] 1. Construction of modified Tim4 protein with C-terminal fusion His tag and Avi tag

[0120] The Avi tag is a short peptide tag consisting of 15 amino acids (GLNDIFEAQKIEWHE (SEQ ID NO: 33)). In the presence of ATP and biotin, BirA connects a biotin to the lysine residue of the Avi tag, thereby achieving biotin labeling of the target protein ( Figure 7 ). In order to facilitate the expression and purification of the modified Tim4 protein, the inventors incorporated a His tag consisting of 8 histidines before the Avi tag. The His tag is small in size and does not affect the protein function, and the purification method is convenient. Structural analysis shows that the C-terminus of the IgV-like domain of the Tim4 protein is farther away from the PS binding site than the N-terminus, and the C-terminal amino acid trend shows a trend away from the entire IgV-like domain. Therefore, the inventors fused the His tag and the Avi tag to the C-terminus of the modified Tim4 protein ( Figure 8 ).

[0121] 2. Analysis of Tim4 protein modified with C-terminal fusion His tag and Avi tag using BirA enzyme

[0122] The modified Tim4 protein (hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi) Avi tag was biotin labeled using the Avi tag biotin labeling kit (BirA method) produced by Biyuntian. According to the table below, 40μM, 30μM, 20μM or 10μM of modified Tim4 protein was added to the 50μl reaction system, incubated at 30℃ for 6 hours, and then SDS-PAGE protein loading buffer was added. SDS-PAGE gel electrophoresis was used, and Western Blot transfer, blocking, and incubation with horseradish peroxidase-labeled streptavidin were performed. The biotin labeling efficiency was detected using ECL color development ( Fig. 9 ), it can be seen that BirA enzyme can effectively complete the biotin labeling of 40 μM modified Tim4 protein. The volume of this reaction system can be reduced or enlarged according to actual needs.

[0123]

[0124] According to the table below, 40 μM modified Tim4 protein was added to 50 μl reaction system, incubated at 30°C for 1 hour, 3 hours and 6 hours, SDS-PAGE protein loading buffer was added, SDS-PAGE gel electrophoresis was performed, Western Blot was transferred, blocked, incubated with horseradish peroxidase-labeled streptavidin, and ECL colorimetric detection of biotin labeling efficiency was performed ( Fig.10 ).

[0125] Component Volume Final Concentration Biotin Ligase Buffer A(10X) 5μl 1X Biotin Ligase Buffer B(10X) 5μl 1X BirA(100X) 0.5μl 1X Modifying Tim4 protein 5μl 40μM <![CDATA[ddH2O]]> 34.5μl -

[0126] It can be seen that 40 μM of the modified Tim4 protein can be effectively labeled with biotin by the BirA enzyme after incubation at 30°C for 6 hours. The volume of this reaction system can be reduced or enlarged according to actual needs.

[0127] Example 3. Expression and purification of modified Tim4 protein

[0128] 1. Expression of Tim4 protein in HEK293F suspension cells

[0129] The inventors tried to express and purify the IgV-like domain protein of human and mouse in the form of inclusion bodies in Escherichia coli BL21 (DE3), but the inclusion body renaturation rate was low, only about 1%, and the purification steps after protein renaturation were complicated, which was limited by low yield and high production time cost. After experimental verification of expression systems such as Escherichia coli, Pichia pastoris, insect cells and mammalian cells, mammalian HEK293F was selected to express the modified Tim4 protein by suspension cell method.

[0130] Codons play an important role in translating genes into protein sequence information during protein synthesis. In order to obtain the best expression effect of human and mouse Tim protein IgV-like domain in HEK293F suspension cells, the inventors optimized the codons of human and mouse Tim protein IgV-like domain based on the analysis of the codon preference of HEK293 cells, and at the same time, by optimizing the CG content of the overall sequence and the codons in the repeat sequence region, the DNA cloning efficiency was improved, the mRNA stability was increased, and the mRNA enhanced transcription and translation efficiency. The codon-optimized base sequence of the IgV-like domain of human Tim1 protein is such as SEQ ID NO: 23, the codon-optimized base sequence of the IgV-like domain of mouse Tim1 protein is such as SEQ ID NO: 24, the codon-optimized base sequence of the IgV-like domain of human Tim3 protein is such as SEQ ID NO: 25, the codon-optimized base sequence of the IgV-like domain of mouse Tim3 protein is such as SEQ ID NO: 26, the codon-optimized base sequence of the IgV-like domain of human Tim4 protein is such as SEQ ID NO: 27, the codon-optimized base sequence of the IgV-like domain of mouse Tim4 protein is such as SEQ ID NO: 28, and the codon-optimized base sequence of the IgV-like domain of human and mouse Tim4 protein expressed in tandem with a flexible linker (GGGGGS) 6 is such as SEQ ID NO: NO:29, flexible linker (GGGGGS) 6 in tandem to express the codon-optimized base sequence of the IgV-like domain of human Tim4 protein, such as SEQ ID NO:30, flexible linker (GGGGGS) 6 in tandem to express the codon-optimized base sequence of the IgV-like domain of mouse Tim4 protein, such as SEQ ID NO:31, and the codon-optimized base sequence of the modified Tim4 protein with C-terminal fusion His tag and Avi tag is such as SEQ ID NO:32.

[0131] The secretory signal peptide of human Tim4 protein was synthesized artificially at the N-terminus, and the IgV-like domains of human and mouse Tim4 proteins were expressed in series through a flexible linker (GGGGGS)6 (referred to as modified Tim4 or hTim4IgV-(GGGGGS)6-mTim4 IgV-His-Avi). The modified Tim4 protein base sequence (SEQID NO:32) containing His tag and Avi tag at the C-terminus was subcloned into the mammalian cell expression vector pcDNA3.4, and the vector plasmid pcDNA3.4-hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi containing the modified Tim4 gene was amplified and extracted. TMSuper PEI transfection reagent was used to transfect pcDNA3.4-hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi into HEK293F suspension cells. The specific transfection steps of suspension cells are as follows (taking 10ml suspension cells as an example):

[0132] a. Inoculation of cells: One day before transfection (18-24 hours), inoculate the appropriate cell density (e.g. 1-1.5×10 6 cells / ml), so that the cell density at the time of transfection on the next day was 2-3×10 6 cells / ml.

[0133] b. Prepare pcDNA3.4-rTim4-His-Avi and BeyoPEI TM Super PEI Compound:

[0134] (a) Preparation of DNA diluent: For 10 ml of suspended cells to be transfected, take a clean sterile centrifuge tube, add 500 μl of cell culture medium and 10 μg of DNA, and mix by gently pipetting with a pipette.

[0135] (b)BeyoPEI TM Preparation of Super PEI transfection reagent diluent: For 10 ml of suspended cells to be transfected, take a clean sterile centrifuge tube, add 450 μl of cell culture medium and 50 μl of BeyoPEI TM Super PEI transfection reagent, and mix gently by pipetting with a gun.

[0136] (c)DNA and BeyoPEI TM Preparation of Super PEI compound: Prepared BeyoPEI TM Add the Super PEI transfection reagent diluent to the DNA diluent and incubate at room temperature for 10-20 minutes.

[0137] c. Transfected cells:

[0138] (a) Mix 1 ml DNA with BeyoPEI TM The Super PEI complex was evenly added dropwise to 10 ml of suspended cells.

[0139] (b) After culturing for 72 hours at 37°C, 80% humidity and 8% CO2, the cell supernatant was collected, transferred to the membrane by Western Blot, blocked, and incubated with horseradish peroxidase-labeled His tag antibody, and the expression of rTim4-His-Avi protein in HEK293F suspension cells was verified by ECL color development ( Fig.11 ).

[0140] 2. Purification of modified Tim4 protein and biotin-labeled modified Tim4 protein

[0141] According to the above conditions for transfecting HEK293F suspension cells with pcDNA3.4-hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi, the culture volume was expanded according to actual needs, and the cell culture medium supernatant was collected. The purification process of modified Tim4 protein and biotin-labeled modified Tim4 protein is shown in Fig.12 .

[0142] a. Enrichment of modified Tim4 protein by reduction-resistant chelating nickel affinity chromatography resin

[0143] (a) Equilibration: Pre-equilibrate the reduction-resistant chelating nickel affinity chromatography resin with 3-5 filler volumes in the following equilibration solution: 10 mM Tris pH 7.4, 500 mM NaCl, 1 mM EDTA.

[0144] (b) Loading: Add the equilibrated reduction-resistant chelating nickel affinity chromatography resin to the collected cell culture supernatant and place on a shaker at 4°C. After incubation for 1 hour, recover the resin by gravity column and wash the filler with 3-5 filler volumes of equilibration solution.

[0145] (c) Elution: The modified Tim4 protein was eluted from the nickel affinity chromatography resin with 3-5 filler volumes of elution solution: 10 mM Tris pH 7.4, 500 mM NaCl, 200 mM imidazole, 1 mM EDTA.

[0146] b. Use BeyoDesalt produced by Biyuntian TM G-25 desalting column to replace the modified Tim4 solution

[0147] (a) Balance: BeyoDesalt TM G-25 Desalting Column connected to The desalting column was equilibrated with 5 column volumes (CV) of 1X PBS buffer at a flow rate of 5 ml / min.

[0148] (b) Sample loading and elution: Set the program: sample injection volume (Inject volume) is 20ml, flow rate (Flowrate) is 5-20ml / min, collection volume (Fraction volume) is 5ml, alarm pressure (Alarm pressure) is 0.5MPa, elution volume (Elute volume) is 1CV (Column Volume), turn on the UV monitor (UV monitor) and conductivity monitor (Conductivity monitor). Run BeyoDesalt TM G-25 desalting column elution procedure, observe the UV absorption peak and collect the separated samples.

[0149] c. The modified Tim4 protein Avi tag was biotin-labeled using BirA enzyme. For specific operations, see Example 2.

[0150] d. Separation of biotin-labeled modified Tim4 protein from BirA enzyme and Biotin by reduction-resistant chelating nickel affinity chromatography resin:

[0151] (a) Equilibration: Pre-equilibrate the reduction-resistant chelating nickel affinity chromatography resin with 3-5 filler volumes in the following equilibration solution: 10 mM Tris pH 7.4, 500 mM NaCl, 1 mM EDTA.

[0152] (b) Loading: Add the equilibrated reduction-resistant chelating nickel affinity chromatography resin to the solution containing BirA enzyme, Biotin and biotin-labeled modified Tim4 protein, shake at 4°C, incubate for 1 hour, recover the resin through a gravity column, and wash the filler with 3-5 filler volumes of the equilibration solution.

[0153] (c) Elution: The biotin-labeled modified Tim4 protein was eluted from the nickel affinity chromatography resin with 3-5 filler volumes of elution solution: 10 mM Tris pH 7.4, 500 mM NaCl, 200 mM imidazole, 1 mM EDTA.

[0154] e. Use BeyoDesalt produced by Biyuntian TM The G-25 desalting column replaces the biotin-labeled modified Tim4 protein solution into the final storage solution:

[0155] (a) Balance: BeyoDesalt TM G-25 Desalting Column connected to The system was operated at a flow rate of 5 ml / min and the desalting column was equilibrated with 5 column volumes (CV) of 20 mM Tris pH 7.6, 137 mM NaCl buffer.

[0156] (b) Sample loading and elution: Set the program: sample injection volume (Inject volume) is 20ml, flow rate (Flowrate) is 5-20ml / min, collection volume (Fraction volume) is 5ml, alarm pressure (Alarm pressure) is 0.5MPa, elution volume (Elute volume) is 1CV (Column Volume), turn on the UV monitor (UV monitor) and conductivity monitor (Conductivity monitor). Run BeyoDesalt TM G-25 desalting column elution procedure, observe the UV absorption peak and collect the separated samples.

[0157] The biotin-labeled modified Tim4 protein purified by the above steps was tested for protein purity and concentration by SDS-PAGE electrophoresis. Fig.13 .

[0158] Example 4. Testing the ability and loading capacity of streptavidin magnetic beads and gel-bound biotin-labeled modified Tim4 protein

[0159] The molecular weight of streptavidin is 55kD, and it can bind to biotin with high specificity. The affinity constant of streptavidin and biotin is Kd=10 -15 Streptavidin is a 4-mer protein that can bind to 4 biotin molecules at the same time. TM Streptavidin Magnetic Beads and Streptavidin Agarose are combined with biotin to modify the Tim4 protein.

[0160] 1. Test the ability and loading capacity of streptavidin magnetic beads to bind biotin-labeled modified Tim4 protein

[0161] a. Washing of Streptavidin Magnetic Beads: Use a pipette to gently blow to fully resuspend the Streptavidin Magnetic Beads, take 50μl and place in a 1.5ml centrifuge tube for later use. Place on a magnetic stand for separation for 1 minute before use, and remove the supernatant. Add about 0.5ml binding solution (TBS, 0.0005-0.05% Tween-20), and use a pipette to gently blow to resuspend the Streptavidin Magnetic Beads. Place on a magnetic stand for separation for 10 seconds, remove the supernatant, and complete one washing step. Then follow this washing step, wash twice, and finally remove the supernatant.

[0162] b. Binding of biotin-labeled modified Tim4 protein to streptavidin magnetic beads: add 20 μg, 30 μg, 40 μg and 50 μg of biotin-labeled modified Tim4 protein in a total volume of 50 μl, respectively, oscillate to resuspend the magnetic beads, place on a rotating mixer, and incubate at 4°C for 1 hour.

[0163] c. Washing of biotin-labeled modified Tim4 protein and streptavidin magnetic beads: Place a 1.5ml centrifuge tube in a handheld centrifuge and centrifuge for 3-5 seconds, fix it on a magnetic rack, and let it stand for 1 minute; after the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant; add about 0.5ml binding solution (TBS, 0.0005-0.05% Tween-20), and use a pipette to gently blow and resuspend the streptavidin magnetic beads. Place it on a magnetic rack for separation for 10 seconds, remove the supernatant, and complete a washing step. Then follow this washing step and wash twice.

[0164] d. Determine the ability and loading capacity of streptavidin magnetic beads to bind to biotin-labeled modified Tim4 protein: add 50 μl of lX SDS-PAGE protein loading buffer to a 1.5 ml centrifuge tube, perform SDS-PAGE gel electrophoresis, transfer to a Western Blot membrane, block, incubate with horseradish peroxidase-labeled streptavidin, use ECL colorimetric detection, and Fig.14 The results showed that 50 μl of streptavidin magnetic beads could effectively bind 20-50 μg of biotin-labeled modified Tim4 protein.

[0165] 2. Test the binding capacity of streptavidin gel to biotin-labeled modified Tim4 protein

[0166] a. Cleaning of streptavidin gel: Gently resuspend the streptavidin gel to form a uniform gel suspension as much as possible, take 50μl and place it in a 1.5ml centrifuge tube for use. Add about 0.5ml binding solution (TBS, 0.0005-0.05% Tween-20), gently resuspend the streptavidin gel. Centrifuge at 600×g at 4℃ for 5 minutes, carefully remove the supernatant, do not suck up the gel, and complete a washing step. Then follow this washing step, wash twice, and finally remove the supernatant.

[0167] b. Binding of biotin-labeled modified Tim4 protein to streptavidin gel: add 50 μg, 60 μg, 80 μg and 100 μg of biotin-labeled modified Tim4 protein in a total volume of 50 μl, respectively, oscillate to resuspend the gel, place on a rotating mixer, and incubate at 4°C for 1 hour.

[0168] c. Washing of biotin-labeled modified Tim4 protein and streptavidin gel: Place a 1.5 ml centrifuge tube in a centrifuge and centrifuge at 600 × g at 4°C for 5 minutes, carefully remove the supernatant without sucking the gel, add about 0.5 ml binding solution (TBS, 0.0005-0.05% Tween-20), gently resuspend the streptavidin gel, centrifuge at 600 × g at 4°C for 5 minutes, carefully remove the supernatant, and complete a washing step. Then follow this washing step, wash twice, and finally remove the supernatant.

[0169] d. Determine the ability and loading capacity of streptavidin gel to bind biotin-labeled modified Tim4 protein: add 50 μl of lX SDS-PAGE protein loading buffer to a 1.5 ml centrifuge tube, use SDS-PAGE gel electrophoresis, transfer to the membrane by Western Blot, block, incubate with horseradish peroxidase-labeled streptavidin, and use ECL color development for detection.

[0170] according to Fig.15 The results showed that 50 μl of streptavidin gel could effectively bind 50-100 μg of biotin-labeled modified Tim4 protein.

[0171] Example 5. Purification of extracellular vesicles by modifying Tim4 protein magnetic beads

[0172] 1. Solution preparation

[0173] Enhancer: 1M CaCl2 in TBS.

[0174] Exosome Capture Immobilizing Buffer: TBS, 0.1% BSA, 0.0005% Tween-20.

[0175] Wash Buffer: TBS, 0.0005% Tween 20.

[0176] Elution Buffer: 10mM EDTA pH8.0, PBS.

[0177] 2. Purification of extracellular vesicles by modifying Tim4 protein magnetic beads

[0178] a. Preparation of extracellular vesicle capture magnetic beads

[0179] (a) Use a pipette to gently pipette to fully resuspend the streptavidin magnetic beads. Take 50 μl and place it in a 1.5 ml centrifuge tube. Fix the 1.5 ml reaction tube on a dedicated magnetic stand and let it stand for about 1 minute. After the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant.

[0180] (b) Add 500 μl of Exosome Capture Immobilizing Buffer to a 1.5 ml centrifuge tube, remove it from the magnetic rack, and mix it using a vortex mixer for 5-10 seconds; centrifuge the 1.5 ml centrifuge tube in a handheld centrifuge for 3-5 seconds, fix it on the magnetic rack, and let it stand for 1 minute; after the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant.

[0181] (c) Add 500 μl Exosome Capture Immobilizing Buffer and 50 μg biotin-labeled modified Tim4 protein to a 1.5 ml centrifuge tube, incubate at 4°C, and rotate to mix for 10 minutes.

[0182] (d) Place the 1.5 ml centrifuge tube in a handheld centrifuge and centrifuge for 3-5 seconds. Fix the tube on a magnetic rack and let it stand for 1 minute. After the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant.

[0183] (e) Add 500 μl of Exosome Capture Immobilizing Buffer to a 1.5 ml centrifuge tube, remove it from the magnetic rack, and mix it using a vortex mixer for 5-10 seconds; centrifuge the 1.5 ml centrifuge tube in a handheld centrifuge for 3-5 seconds, fix it on the magnetic rack, and let it stand for 1 minute; after the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant.

[0184] b. Modification of Tim4 protein magnetic beads to capture extracellular vesicles

[0185] (a) Add 2 μl Enhancer to 1 ml of 10-fold concentrated HEK293F serum-free medium supernatant, vortex mix for 5-10 seconds, transfer to a 1.5 ml reaction tube containing exosome capture fixed magnetic beads, vortex mix for 5-10 seconds; incubate at 4°C and rotate to mix for 1 hour.

[0186] (b) Place a 1.5 ml centrifuge tube in a handheld centrifuge and centrifuge for 3-5 seconds. Fix the tube on a magnetic rack and let it stand for 1 minute. After the magnetic beads are completely adsorbed to the tube wall, use a micropipette to remove the supernatant.

[0187] c. Washing of magnetic beads that capture extracellular vesicles:

[0188] (a) Add 6 μl of Enhancer to 3 ml of Wash Buffer and mix using a vortex mixer.

[0189] (b) Add 1 ml Wash Buffer (containing Enhancer) to the 1.5 ml reaction tube containing extracellular vesicle magnetic beads and mix with a vortex mixer for 5-10 seconds; centrifuge the 1.5 ml reaction tube on a desktop centrifuge for 3-5 seconds, fix it on a magnetic stand, and let it stand for 1 minute. After the magnetic beads are completely adsorbed to the tube wall, use a pipette to remove the supernatant.

[0190] (c) Repeat step (b) twice, centrifuge the 1.5 ml reaction tube in a tabletop centrifuge for 3-5 seconds, fix it on a magnetic rack, and let it stand for 1 minute. After the magnetic beads are completely attached to the tube wall, use a pipette to remove the remaining supernatant.

[0191] d. Elution of extracellular vesicles: Add 50μl Elution Buffer to a 1.5ml reaction tube, remove from the magnetic rack, and mix using a vortex mixer for 5-10 seconds; centrifuge the 1.5ml reaction tube in a desktop centrifuge for 3-5 seconds, fix it on the magnetic rack, let it stand for 1 minute until the magnetic beads are completely adsorbed to the tube wall, and transfer the supernatant to a new 1.5ml centrifuge tube; add 50μl Elution Buffer to the 1.5ml reaction tube again, remove from the magnetic rack, and mix using a vortex mixer for 5-10 seconds; centrifuge the 1.5ml reaction tube in a desktop centrifuge for 3-5 seconds, fix it on the magnetic rack, let it stand for 1 minute until the magnetic beads are completely adsorbed to the tube wall, and then combine the 50μl elution buffer with the previous 50μl elution buffer.

[0192] e. Western Blot detection of purified extracellular vesicles: 30 μl of elution solution was added with 10 μl lX SDS-PAGE protein loading buffer, and SDS-PAGE gel electrophoresis was performed. Western Blot transfer, blocking, incubation with CD81 mouse monoclonal antibody, incubation with horseradish peroxidase-labeled secondary antibody, and ECL color detection were performed according to Fig.16 The results showed that by modifying the Tim4 protein magnetic beads, extracellular vesicles can be effectively bound and purified.

[0193] Example 6. Comparison of the effect of modified Tim4 protein labeled with biotin and Tim4-Fc protein labeled with biotin randomly on binding to streptavidin magnetic beads and pure extracellular vesicles

[0194] The protein containing mouse Tim4 extracellular end fused with the Fc domain of mouse IgG1 was randomly labeled with biotin using the Biotin Labeling Kit-NH2. Fig.17A). Using the method of Example 2, the modified Tim4 protein Avi tag was specifically labeled with biotin using BirA enzyme ( Fig.17 B). The method of Example 4 was used to bind the mTim4-Fc protein randomly labeled with biotin and the modified Tim4 protein labeled with biotin at a fixed point to the streptavidin magnetic beads. Since all sides of the randomly labeled Tim4-Fc protein may be labeled with biotin, when it binds to the streptavidin magnetic beads, it will bind to the surface of the streptavidin magnetic beads at different angles like rolling dice, which results in the PS binding pocket of part of the mTim4-Fc protein being blocked by the contact surface ( Fig.18 A). The modified Tim4 protein of the present invention can be bound to the surface of streptavidin magnetic beads at a fixed angle through the biotin specifically located at the C-terminus, so that the PS binding site of the modified Tim4 protein is fully exposed ( Fig.18 B).

[0195] The extracellular vesicles in the supernatant of HEK293F serum-free culture medium were purified by the method of Example 5. The results of Western Blot detection are shown in Fig.19 The purification efficiency of extracellular vesicles was calculated based on the grayscale results of Western Blot detection bands. Fig. 20 It can be seen that compared with the magnetic beads of Tim4-Fc protein randomly labeled with biotin, the magnetic beads prepared by modifying the Tim4 protein of the present invention have higher efficiency and loading capacity in capturing extracellular vesicles in the sample.

[0196] Sequence information Human Tim1 amino acid sequence (SEQ ID NO: 1):

[0197] MHPQVVILSLILHLADSVAGSVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDTRYKLLGDLSRRDVSLTIENTAVSDSGVYCCRVEHRGWFNDMKITVSLEIVPPKVTTTPIVTTVPTVTTVRTSTTVPTTTTVPMTTVPTTTVPTTMSIPTTTTVLTTM TVSTTTTSVPTTTSIPTTTSVPVTTTVSTFVPPMPLPRQNHEPVATSPSSPQPAETHPTTLQGAIRREPTSSPLYSYTTDGNDTVTESSDGLWNNNQTQLFLEHSLLTANTTKGIYAGVCISVLVLLALLGVIIAKKYFFKKEVQQLSVSFSSLQIKALQNAVEKEVQAEDNIYIENSLYATD

[0198] Mouse Tim1 Amino Acid Sequence (SEQ ID NO:2):

[0199] MNQIQVFISGLILLLPGAVDSYVEVKGVVGHPVTLPCTYSTYRGITTTCWGRGQCPSSACQNTLIWTNGHRVTYQKSSRYNLKGHISEGDVSLTIENSVESDSGLYCCRVEIPGWFNDQKVTFSLQVKPEIPTRPPTRPTTTRPTATGRPTTISTRSTHVPTSIRVSTSTPPTSTHTWTHKPEPTTFCPHETTAEVTGIPSHTPTDWNGTVTSSGDTWSNHTEAIPPGKPQKNPTKGFYVGICIAALLLLLLVSTVAITRYILMKRKSASLSVVAFRVSKIEALQNAAVVHSRAEDNIYIVEDRP

[0200] Human Tim3 Amino Acid Sequence (SEQ ID NO:3):

[0201] MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFKWYSHSKEKIQNLSLISLANLPPSGLANAVAEGIRSEENIYTIEENVYEVEEPNEYYCYVSSRQQPSQPLGCRFAMP

[0202] Mouse Tim3 Amino Acid Sequence (SEQ ID NO:4):

[0203] MFSGLTLNCVLLLLQLLLARSLENAYVFEVGKNAYLPCSYTLSTPGALVPMCWGKGFCPWSQCTNELLRTDERNVTYQKSSRYQLKGDLNKGDVSLIIKNVTLDDHGTYCCRIQFPGLMNDKKLELKLDIKAAKVTPAQTAHGDSTTASPRTLTTERNGSETQTLVTLHNNNGTKISTWADEIKDSGETIRTAIHIGVGVSAGLTLALIIGVLILKWYSCKKKKLSSLSLITLANLPPGGLANAGAVRIRSEENIYTIEENVYEVENSNEYYCYVNSQQPS

[0204] Human Tim4 amino acid sequence (SEQ ID NO: 5):

[0205] MSKEPLILWLMIEFWWLYLTPVTSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINVRLNLQRASTTTHRTATTTTRRTTTTSPTTTRQMTTTPAALPTTVVTTPDLTTGTPLQMTTIAVFTTANTCLSLTPSTLPEEATGLLTPEPSKEGPILTAESETVLPSDSWSSVESTSADTVLLTSKESKVWDLPSTSHVSMWKTSDSVSSPQPGASDTAVPEQNKTTKTGQMDGIPMSMKNEMPISQLLMIIAPSLGFVLFALFVAFLLRGKLMETYCSQKHTRLDYIGDSKNVLNDVQHGREDEDGLFTL

[0206] Mouse Tim4 amino acid sequence (SEQ ID NO: 6):

[0207] MSKGLLLLWLVTELWWLYLTPAASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGKGSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIEVPGWFNDVKKNVRLELRRATTTKKPTTTTRPTTTPYVTTTTPELLPTTVMTTSVLP TTTPPQTLATTAFSTAVTTCPSTTPGSFSQETTKGSAFTTESETLPASNHSQRSMMTISTDIAVLRPTGSNPGILPSTSQLTTQKTTLTTSESLQKTTKSHQINSRQTILIIACCVGFVLMVLLFLAFLLRGKVTGANCLQRHKRPDNTEDSDSVLNDMSHGRDDEDGIFTL

[0208] The amino acid sequence of the IgV-like domain of human Tim1 protein (SEQ ID NO: 7):

[0209] SVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDTRYKLLGDLSRRDVSLTIENTAVSDSGVYCCRVEHRGWFNDMKITVS

[0210] The amino acid sequence of the IgV-like domain of mouse Tim1 protein (SEQ ID NO: 8):

[0211] YVVKGVVGHPVTLPCTYSTYRGITTTCWGRGQCPSSACQNTLIWTNGHRVTYQKSSRYNLKGHISEGDVSLTIENSVESDSGLYCCRVEIPGWFNDQKVT

[0212] The amino acid sequence of the IgV-like domain of human Tim3 protein (SEQ ID NO: 9):

[0213] SEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFN

[0214] The amino acid sequence of the IgV-like domain of mouse Tim3 protein (SEQ ID NO: 10):

[0215] RSLENAYVFEVGKNAYLPCSYTLSTPGALVPMCWGKGFCPWSQCTNELLRTDERNVTYQKSSRYQLKGDLNKGDVSLIIKNVTLDDHGTYCCRIQFPGLMNDKKLE

[0216] The amino acid sequence of the IgV-like domain of human Tim4 protein (SEQ ID NO: 11):

[0217] ETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKIN

[0218] The amino acid sequence of the IgV-like domain of mouse Tim4 protein (SEQ ID NO: 12):

[0219] ASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGKGSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIEVPGWFNDVKKNVR

[0220] Amino acid sequence of secretory signal peptide of human Tim1 protein (SEQ ID NO: 13):

[0221] MHPQVVILSLILHLADSVAG

[0222] The secretory signal peptide amino acid sequence of mouse Tim1 protein (SEQ ID NO: 14):

[0223] MNQIQVFISGLILLLPGAVDS

[0224] Secretory signal peptide amino acid sequence of human Tim3 protein (SEQ ID NO: 15):

[0225] MFSHLPFDCVLLLLLLLLTRS

[0226] The secretory signal peptide amino acid sequence of mouse Tim3 protein (SEQ ID NO: 16):

[0227] MFSGLTLNCVLLLLQLLLA

[0228] The secretory signal peptide amino acid sequence of human Tim4 protein (SEQ ID NO: 17):

[0229] MSKEPLILWLMIEFWWLYLTPVTS

[0230] The secretory signal peptide amino acid sequence of mouse Tim4 protein (SEQ ID NO: 18):

[0231] MSKGLLLLWLVTELWWLYLTPA

[0232] Flexible linker sequence (GGGGGS) 6 tandemly expresses the amino acid sequence of the IgV-like domain of human and mouse Tim4 protein (SEQ ID NO: 19):

[0233] MSKEPLILWLMIEFWWLYLTPVTSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINGGGGGSGG GGGSGGGGGSGGGGGSGGGGGSGGGGGSASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGKGSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIEVPGWFNDVKKNVR

[0234] Flexible linker sequence (GGGGGS) 6 tandemly expresses the amino acid sequence of the IgV-like domain of human Tim4 protein (SEQ ID NO: 20):

[0235] MSKEPLILWLMIEFWWLYLTPVTSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINGGGGGS GGGGGSGGGGGSGGGGGSGGGGGSGGGGGSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKIN

[0236] Flexible linker sequence (GGGGGS) 6 tandemly expresses the amino acid sequence of the IgV-like domain of mouse Tim4 protein (SEQ ID NO: 21):

[0237] MSKGLLLLWLVTELWWLYLTPAASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGKGSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIEVPGWFNDVKKNVRGGGGGSG GGGGSGGGGGSGGGGGSGGGGGSGGGGGSASEDTIIGFLGQPVTLPCHYLSWSQSRNSMCWGKGSCPNSKCNAELLRTDGTRIISRKSTKYTLLGKVQFGEVSLTISNTNRGDSGVYCCRIEVPGWFNDVKKNVR

[0238] The amino acid sequence of the IgV-like domain of human and mouse Tim4 protein fused with His tag and Avi tag at the C-terminus (referred to as modified Tim4 or hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi) (SEQ ID NO: 22) is tandemly expressed by a flexible linker (GGGGGS)6:

[0239] MSKEPLILWLMIEFWWLYLTPVTSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINGGGGGSGGGGGS GGGGGSGGGGGSGGGGGSGGGGGSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINGSHHHHHHHGS GLNDIFEAQKIEWHE

[0240] The codon-optimized base sequence of the IgV-like domain of human Tim1 protein (SEQ ID NO: 23):

[0241] TCCGTGAAAGTGGGCGGAGAGGCGGGCCCATCCGTGACACTTCCCTGTCATTATTCTGGTGCGGTAACCTCTATGTGCTGGAATAGAGGAAGTTGTTCACTCTTCACCTGTCAGAACGGCATAGTTTGGACAAATGGAACGCACGTCACTTATCGAAAGGACACGCGGTACAAGTTGCTTGGGGACCTTTCACGCCGGGACGTATCTCTTACCATTGAAAACACCGCCGTCTCAGACAGCGGCGTTTACTGCTGTCGAGTAGAGCATAGAGGTTGGTTTAACGATATGAAAATAACTGTGAGC

[0242] Base sequence with codon optimization of the IgV-like domain of mouse Tim1 protein (SEQ ID NO:24):

[0243] TATGTCGAGGTTAAGGGTGTTGTAGGTCACCCAGTCACCCTCCCTTGCACTTACTCTACTTATAGGGGCATCACCACTACGTGTTGGGGACGAGGCCAATGTCCTAGCTCTGCATGTCAGAACACTTTGATTTGGACAAACGGACACAGAGTTACTTACCAGAAGTCTAGCAGGTATAATCTGAAGGGTCACATCTCCGAAGGAGACGTCAGTCTGACAATCGAGAACTCAGTTGAGTCAGATTCTGGACTGTATTGCTGTAGGGTGGAAATACCCGGCTGGTTCAACGATCAGAAGGTTACT

[0244] Base sequence with codon optimization of the IgV-like domain of human Tim3 protein (SEQ ID NO:25):

[0245] TCTGAGGTTGAGTACCGCGCAGAAGTGGGCCAAAATGCGTATCTCCCTTGTTTTTACACTCCCGCAGCACCGGGTAACCTCGTACCCGTATGCTGGGGTAAAGGGGCCTGCCCCGTTTTCGAGTGCGGTAACGTGGTTCTTCGGACCGACGAGC GCGATGTGAACTACTGGACTTCTAGATACTGGTTGAACGGTGACTTTCGCAAGGGAGACGTAAGTTTGACAATCGAAAACGTTACATTGGCGGATAGTGGTATTTATTGTTGTCGCATCCAGATTCCAGGTATTATGAATGACGAGAAATTTAAC

[0246] The codon-optimized base sequence of the IgV-like domain of mouse Tim3 protein (SEQ ID NO: 26):

[0247] CGCTCCTTGGAGAATGCGTATGTGTTCGAAGTCGGCAAGAATGCTTATCTTCCCTGTAGCTACACTCTCTCTACACCTGGAGCCCTCGTTCCAATGTGTTGGGGCAAAGGGTTCTGTCCTTGGTCTCAATGCACCAATGAACTCTTGAGGACAGACGAA CGGAATGTAACGTACCAGAAATCTTCCCGCTATCAGCTCAAAGGTGATTTGAATAAAGGCGATGTCAGTCTTATCATTAAAAATGTGACTCTGGACGACCACGGTACATACTGTTGCAGAATTCAATTCCCAGGTCTTATGAATGATAAAAAACTGGAA

[0248] The codon-optimized base sequence of the IgV-like domain of human Tim4 protein (SEQ ID NO: 27):

[0249] GAAACCGTTGTGACAGAAGTGCTCGGCCATAGAGTGACACTGCCCTGTTTGTACTCAAGTTGGTCTCACAATTCAAACTCCATGTGTTGGGGTAAGGATCAGTGCCCCTACAGTGGATGTAAGGAGGCGCTTATAAGGACTGACGGTATGAGA GTAACGAGTAGGAAAAGCGCGAAGTATCGGTTGCAAGGCACCATACCCAGAGGCGACGTTTCACTGACCATATTGAATCCCAGTGAAAGTGATTCTGGGGTTTTATTGCTGTCGAATTGAAGTCCCAGGATGGTTCAATGATGTAAAAATCAAC

[0250] The codon-optimized base sequence of the IgV-like domain of mouse Tim4 protein (SEQ ID NO: 28):

[0251] GCAAGTGAGGACACAATTATTGGTTTCTTGGGCCAACCGGTCACACTTCCCTGTCACTATCTCTCATGGTCTCAAAGTCGCAATTCTATGTGTTGGGGGAAAGGCAGTTGTCCTAACTCTAAATGCAATGCCGAGCTCCTGCGGACTGATGGGACCCGC ATAATAAGTAGGAAATCCACAAAATACACACTGCTTGGTAAAGTCCAGTTCGGAGAAGTTTCTCTGACAATCTCTAACACAAATAGAGGAGATTCTGGGGTCTATTGTTGCCGCATTGAAGTTTCCAGGCTGGTTCAACGACGTCAAAAAGAACGTCCGC

[0252] Flexible linker sequence (GGGGGS) 6 tandemly expresses the codon-optimized base sequence of the IgV-like domain of human and mouse Tim4 protein (SEQ ID NO: 29):

[0253] ATGTCAAAGGAGCCTTTGATCTTGTGGCTTATGATAGAATTCTGGTGGCTGTATCTGACTCCCGTGACTAGTGAAACGGTCGTGACCGAGGTCTTGGGGCACAGGGTGACGCTGCCCTGCCTGTACTCTTCTTGGTCTCACAATTCTAACTCAATGTGTTGGGGCAAAGATCAGTGCCCTTACAGTGGATGCAAAGAGGCTCTTATAAGGACAGACGGGATGAGGGTAACGTCCAGGAAGAGTGCTAAATATCGGCTTCAGGGTACGATTCCCAGGGGGGATGTGAGCCTTACCATACTGAACCCTAGTGAGAGTGATTCAGGTGTCTACTGCTGTAGAATCGAAGTACCTGGGTGGTTTAACGACGTAAAAATCAACGGGGGTGGGGGCGGTTCAGGAGGAGGCGGGGGGTCTGGTGGTGGCGGCGGGTCTGGAGGAGGCGGAGGCTCCGGTGGAGGAGGAGGGTCAGGAGGAGGTGGTGGTTCAGCAAGTGAGGACACAATTATTGGTTTCTTGGGCCAACCGGTCACACTTCCCTGTCACTATCTCTCATGGTCTCAAAGTCGCAATTCTATGTGTTGGGGGAAAGGCAGTTGTCCTAACTCTAAATGCAATGCCGAGCTCCTGCGGACTGATGGGACCCGCATAATAAGTAGGAAATCCACAAAATACACACTGCTTGGTAAAGTCCAGTTCGGAGAAGTTTCTCTGACAATCTCTAACACAAATAGAGGAGATTCTGGGGTCTATTGTTGCCGCATTGAAGTTCCAGGCTGGTTCAACGACGTCAAAAAGAACGTCCGC

[0254] Base sequence of codon-optimized IgV-like domain of human Tim4 protein tandemly expressed with flexible linker sequence (GGGGGS)6 (SEQ ID NO: 30):

[0255] ATGTCCAAAGAGCCCTTGATTCTCTGGCTTATGATCGAGTTTTGGTGGCTGTATCTGACCCCGGTCACCTCTGAGACCGTGGTAACCGAAGTACTGGGGCACCGAGTTACCCTCCCATGTCTCTACTCTTCTTGGAGTCATAATTCAAACTCAATGTGCTGGGGCAAGGACCAGTGTCCGTACAGTGGCTGCAAAGAAGCACTCATACGGACAGATGGCATGCGAGTCACGTCAAGAAAGTCTGCCAAGTATAGATTGCAGGGCACCATTCCTCGAGGGGATGTGTCCCTCACCATTTTGAACCCTAGTGAGAGTGATAGCGGAGTTTATTGTTGCCGAATCGAAGTCCCGGGCTGGTTCAATGACGTGAAAATCAACGGAGGAGGAGGAGGCAGTGGAGGAGGCGGCGGCTCAGGTGGAGGGGGGGGATCCGGTGGTGGTGGAGGCTCAGGAGGCGGTGGCGGCAGTGGCGGAGGAGGAGGATCAGAGACCGTTGTTACCGAAGTCCTCGGCCACAGGGTAACTCTTCCGTGTCTTTACTCTAGCTGGTCACACAACAGCAACTCCATGTGTTGGGGAAAAGATCAGTGTCCTTATAGCGGTTGCAAGGAAGCACTCATACGAACTGACGGCATGCGGGTGACGTCCCGGAAGAGCGCAAAATATAGGCTGCAGGGAACGATACCGCGGGGAGATGTCTCACTGACCATCCTCAATCCATCCGAGTCTGATAGCGGGGTCTACTGTTGTCGGATCGAGGTACCTGGTTGGTTTAACGACGTCAAGATCAAC

[0256] Base sequence (SEQ ID NO: 31) of codon-optimized IgV-like domain of mouse Tim4 protein tandemly expressed with flexible linker sequence (GGGGGS)6:

[0257] ATGAGTAAGGGGCTGCTGCTCCTCTGGCTCGTTACCGAATTGTGGTGGCTTTACCTCACTCCGGCAGCAAGTGAGGACACAATTATTGGTTTCTTGGGCCAACCGGTCACACTTCCCTGTCACTATCTCTCATGGTCTCAAAGTCGCAATTCTATGTGTTGGGGGAAAGGCAGTTGTCCTAACTCTAAATGCAATGCCGAGCTCCTGCGGACTGATGGGACCCGCATAATAAGTAGGAAATCCACAAAATACACACTGCTTGGTAAAGTCCAGTTCGGAGAAGTTTCTCTGACAATCTCTAACACAAATAGAGGAGATTCTGGGGTCTATTGTTGCCGCATTGAAGTTCCAGGCTGGTTCAACGACGTCAAAAAGAACGTCCGCGGGGGTGGGGGGGGATCAGGTGGGGGTGGAGGTAGCGGTGGTGGAGGGGGAAGTGGAGGAGGCGGTGGTAGTGGTGGGGGAGGGGGTTCTGGTGGTGGCGGAGGTTCAGCAAGTGAGGACACAATTATTGGTTTCTTGGGCCAACCGGTCACACTTCCCTGTCACTATCTCTCATGGTCTCAAAGTCGCAATTCTATGTGTTGGGGGAAAGGCAGTTGTCCTAACTCTAAATGCAATGCCGAGCTCCTGCGGACTGATGGGACCCGCATAATAAGTAGGAAATCCACAAAATACACACTGCTTGGTAAAGTCCAGTTCGGAGAAGTTTCTCTGACAATCTCTAACACAAATAGAGGAGATTCTGGGGTCTATTGTTGCCGCATTGAAGTTCCAGGCTGGTTCAACGACGTCAAAAAGAACGTCCGC

[0258] Base sequence (SEQ ID NO:32) of codon-optimized flexible linker (GGGGGS)6 tandemly expressed IgV-like domain of human and mouse Tim4 proteins with C-terminal fusion of His tag and Avi tag (referred to as modified Tim4 or hTim4 IgV-(GGGGGS)6-mTim4 IgV-His-Avi):

[0259] ATGTCAAAGGAGCCTTTGATCTTGTGGCTTATGATAGAATTCTGGTGGCTGTATCTGACTCCCGTGACTAGTGAAACGGTCGTGACCGAGGTCTTGGGGCACAGGGTGACGCTGCCCTGCCTGTACTCTTCTTGGTCTCACAATTCTAACTCAATGTGTTGGGGCAAAGATCAGTGCCCTTACAGTGGATGCAAAGAGGCTCTTATAAGGACAGACGGGATGAGGGTAACGTCCAGGAAGAGTGCTAAATATCGGCTTCAGGGTACGATTCCCAGGGGGGATGTGAGCCTTACCATACTGAACCCTAGTGAGAGTGATTCAGGTGTCTACTGCTGTAGAATCGAAGTACCTGGGTGGTTTAACGACGTAAAAATCAACGGGGGTGGGGGCGGTTCAGGAGGAGGCGGGGGGTCTGGTGGTGGCGGCGGGTCTGGAGGAGGCGGAGGCTCCGGTGGAGGAGGAGGGTCAGGAGGAGGTGGTGGTTCAGCAAGTGAGGACACAATTATTGGTTTCTTGGGCCAACCGGTCACACTTCCCTGTCACTATCTCTCATGGTCTCAAAGTCGCAATTCTATGTGTTGGGGGAAAGGCAGTTGTCCTAACTCTAAATGCAATGCCGAGCTCCTGCGGACTGATGGGACCCGCATAATAAGTAGGAAATCCACAAAATACACACTGCTTGGTAAAGTCCAGTTCGGAGAAGTTTCTCTGACAATCTCTAACACAAATAGAGGAGATTCTGGGGTCTATTGTTGCCGCATTGAAGTTCCAGGCTGGTTCAACGACGTCAAAAAGAACGTCCGCGGTTCCCACCACCATCATCATCACCACCACGGGAGTGGCTTGAATGACATATTCGAGGCCCAGAAAATTGAATGGCATGAG

[0260] Avi tag amino acid sequence (SEQ ID NO:33):

[0261] GLNDIFEAQKIEWHE

[0262] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several modifications and improvements without departing from the principle of the present invention. These modifications and improvements should also be regarded as the scope of protection of the present invention.

Claims

1. A method for identifying and isolating extracellular membrane vesicles or enveloped viruses from a sample for non-diagnostic purposes, comprising: (1) A binding system is provided, comprising a solid phase carrier, and a protein complex located on the solid phase carrier; the protein complex is operably connected to: an IgV-like domain of a human Tim4 protein as shown in SEQ ID NO: 11, a flexible linker (GGGGGS)×6, and an IgV-like domain of a mouse Tim4 protein as shown in SEQ ID NO: 12; a signal peptide is also provided at the amino terminus of the protein complex, which enables the protein complex to be secreted and expressed; a tag is also provided at the carboxyl terminus of the protein complex, and the tag includes a tag Avi; (2) The sample is loaded into the binding system of (1) to identify and separate the extracellular membrane vesicles or enveloped viruses.

2. The method according to claim 1, characterized in that The carboxyl end of the protein complex includes a tag, and the tag carries a conjugate 1; the solid phase carrier includes a conjugate 2, and the conjugate 2 specifically binds to the conjugate 1, and the protein complex is fixed to the solid phase carrier through the binding.

3. The method according to claim 2, characterized in that The conjugate 1 is biotin, the conjugate 2 is avidin, and the biotin is connected to the label Avi.

4. The method according to claim 1, characterized in that The tags also include purification tags.

5. The method according to claim 1, characterized in that (2), the binding system is in Ca 2+ Binds to extracellular vesicles or enveloped viruses in the presence of 6. The method according to claim 1, characterized in that After step (2), the method further includes the step of detecting extracellular membrane vesicles or enveloped viruses.

7. The method according to claim 6, characterized in that The detection is performed using ELISA or flow cytometry.

8. The method according to claim 7, characterized in that Extracellular vesicles or enveloped viruses are detected by sandwich ELISA using antibodies against extracellular vesicles or enveloped virus surface antigens.

9. A protein complex, wherein the protein complex is operably connected to: the IgV-like domain of human Tim4 protein as shown in SEQ ID NO: 11, a flexible linker (GGGGGS)×6, and the IgV-like domain of mouse Tim4 protein as shown in SEQ ID NO: 12; a signal peptide is also set at the amino terminus of the protein complex, which enables the protein complex to be secreted and expressed; a tag is also set at the carboxyl terminus of the protein complex, and the tag includes a tag Avi.

10. The white composite according to claim 9, characterized in that The tags also include purification tags.

11. A polynucleotide encoding the protein complex according to claim 9 or 10.

12. An expression construct comprising the polynucleotide of claim 11.

13. A method for preparing the protein complex according to claim 9 or 10, comprising: Providing a polynucleotide encoding the protein complex of claim 9 or 10, introducing the polynucleotide into eukaryotic cells using an expression construct, and performing recombinant expression in suspension cells; The eukaryotic cells include: 293 cells and CHO cells.

14. A combined system for identifying and isolating extracellular membrane vesicles or enveloped viruses from a sample, comprising: A solid phase carrier, and the protein complex according to claim 9 or 10 located on the solid phase carrier.

15. The method for preparing the bonding system according to claim 14, comprising: The method of claim 13 is used to prepare a protein complex, wherein the carboxyl end of the protein complex comprises a tag, and the tag is connected to the conjugate 1; The protein complex is fixed on a solid phase carrier, wherein the solid phase carrier includes a conjugate 2, and the conjugate 2 specifically binds to the conjugate 1.

16. The method according to claim 15, characterized in that The conjugate 1 is biotin, and the conjugate 2 is avidin; the biotin is connected to the label Avi.

17. A kit for identifying and isolating extracellular membrane vesicles or enveloped viruses from a sample, comprising: The protein complex according to claim 9 or 10, a polynucleotide encoding the same, or an expression construct containing the polynucleotide.

18. A kit for identifying and isolating extracellular membrane vesicles or enveloped viruses from a sample, comprising: The bonding system of claim 14.